Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XDx to go public in $86m flotation:

This article was originally published in Clinica

Executive Summary

Molecular diagnostics specialist XDx is aiming to fund clinical trials of its lung transplant rejection test by raising up to $86.25m through an IPO. The Brisbane, California-based company is using patient specimens from a lung allograft rejection study it conducted to test the clinical validity of its AlloMap LTx test. XDx focuses on producing non-invasive gene expression-based tests for monitoring transplant rejection and autoimmune diseases, and already markets its AlloMap HTx test for monitoring gene expression in processed blood samples of patients who have received heart transplants. Proceeds from the IPO will also go towards expanding commercialisation of AlloMap HTx. The company will float on the Nasdaq Stock Exchange under the symbol -XDXI".

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel